# Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

> **NCT03710291** · PHASE3 · TERMINATED · sponsor: **Tricida, Inc.** · enrollment: 1480 (actual)

## Conditions studied

- Metabolic Acidosis
- Chronic Kidney Disease

## Interventions

- **DRUG:** TRC101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03710291
- **Lead sponsor:** Tricida, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-20
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-09-27
- **Target enrollment:** 1480 (ACTUAL)
- **Why stopped:** Administrative reasons
- **Last updated:** 2022-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710291, "Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03710291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*